News | June 24, 2022
Silo Pharma expands license agreement and patent portfolio
Silo enters into commercial evaluation license agreement for next generation liposomes
Silo enters into commercial evaluation license agreement for next generation liposomes
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
It is currently available in tablet and injectable dosage forms
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
